Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
SpectraCure AB is a biotechnology company specializing in innovative cancer treatment solutions. The company's primary focus is on developing photodynamic therapy systems, a treatment that uses light-sensitive drugs and light to eradicate cancer cells. SpectraCure AB's technological advances are particularly relevant in treating prostate, pancreatic, and head and neck cancers. By combining medical and precision laser technology, the company aims to provide minimally invasive treatment options that reduce side effects and improve patient outcomes. Operating at the intersection of healthcare and technology, SpectraCure plays a critical role in advancing the field of oncology by offering alternative therapies to traditional methods like chemotherapy and radiation. With its focus on cutting-edge research and development, SpectraCure AB is a significant player in the biotech industry, contributing to the evolving landscape of cancer treatment technologies.
kr 0.00
+kr 0.00 (+0.00%)
EOD Jun 26, 2026 · Twelve Data
ROIC dropped from -15.13% to -40.77%, capital efficiency is deteriorating. Negative free cash flow of -kr 44M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 56M
▼ -143.8% YoY
Op. Margin
—
ROIC
-40.77%
▼ -25.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 43M
▼ -20.0% YoY
Op. Cash Flow (TTM)
-kr 29M
▼ -79.5% YoY
Net Debt
-kr 11M
Net Cash Position
Cash & Equiv.
kr 14M
Continue Research
SpectraCure AB (SPEC.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, SpectraCure AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
SpectraCure AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -40.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SPEC.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.